Clinical Trial Update: Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis [NA]

View source ↗

Summary

A clinical trial evaluating whether Lactobacillus crispatus CRP21 can reduce recurrent bacterial vaginosis, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Vaginosis

Drugs mentioned

• Lactobacillus crispatus CRP21 (Lactobacillus crispatus CRP21)

Snippet

Sponsor: Liaquat University of Medical & Health Sciences | Conditions: Recurrent Bacterial Vaginosis | NA | Status: NOT_YET_RECRUITING